International Psoriasis Council
Advancing Knowledge. Improving Care.
2025 IPC Think Tank – Puerto Rico
Friday, December 5, 2025 | Time: 09:00 – 16:15 AST
HILTON GARDEN INN SAN JUAN CONDADO
Room: Miramar 1, Mezzanine Level
WELCOME AND PROGRAM OVERVIEW
Bruce Strober, MD, PhD, United States
Meet the 2025 IPC Fellows
Moderator: Joel Gelfand, MD, MSCE, United States
SESSION ONE: MECHANISTIC ASPECTS
Epidemiology of Metabolic Syndrome, Cardiovascular Disease, and Psoriasis
Joel Gelfand, MD, MSCE, United States
Shared Genetic Loci Between Psoriasis and Metabolic Syndrome
Anne Bowcock, PhD, United States
Molecular Mechanisms of Psoriasis Immunometabolism: A Comprehensive Overview
Álvaro González-Cantero, MD, PhD, Spain
Serum Adiponectin Levels and Their Association with Cardiometabolic Risk Factors in Patients with Psoriasis
Nehal Mehta, MD, MSCE, FAHA, United States
BREAK
Th17/IL-17, Immunometabolism of Psoriasis and Metabolic Disease
Paolo Gisondi, MD, Italy
Biomarkers to Guide the Future Treatment of Patients with Psoriasis in the Context of Metabolic Syndrome
Kevin Cooper, MD, United States
Breakout Session | Identifying Key Questions from Session One
LUNCH
SESSION TWO: INTERVENTIONS
Does Weight Loss Improve Psoriasis and Reduce the Risk of Psoriatic Arthritis?
Lone Skov, MD, PhD, Denmark
The Pathomechanistic Role of GLP-1 Receptor Agonists in Psoriasis
Wilson Liao, MD, United States
The Treatment of Psoriasis with GLP-1 Receptor Agonists
Anna López Ferrer, MD, PhD, Spain
The Role of the Dermatologist in Obesity and Cardiovascular Disease
Jo Lambert, MD, PhD, Belgium
Breakout Session | Identifying Key Questions from Session Two
BREAK
Voting Session: Prioritization of Topics
CLOSING COMMENTS
Bruce Strober, MD, PhD, United States
In this IPC commentary, Matias Maskin examines evidence from the BADBIR registry demonstrating that first-line biologic therapy in moderate to severe psoriasis leads to faster skin clearance, improved quality of life, and a lower risk of comorbidities. The analysis challenges traditional step-up approaches and supports earlier, patient-centered treatment strategies.
What were the key takeaways from the 2026 AAD Annual Meeting? IPC shares updates on diagnostic challenges, psoriasis therapies, and late-breaking research from leading experts.
A new regional collaboration led by IPC and partner organizations aims to improve diagnosis, treatment, and care coordination for psoriasis and psoriatic arthritis across Latin America.
IPC recognizes its 2025 Fellows as IPC Jr. Councilors following the completion of their fellowship. This transition recognizes their contributions to psoriasis research, education, and global collaboration, and marks their expanded role in the IPC network.
The International Psoriasis Council welcomes Mari Løset and Maxwell Sauder as new Councilors, supporting IPC’s global mission in psoriasis research and care.
In this Take Ten with IPC video, Dr. Leandro Leite discusses the most recent advances in psoriasis over the last year (March 2025 – March 2026). Topics include new guidelines, research, and recent studies.
